Copyright
©The Author(s) 2022.
World J Exp Med. Jul 20, 2022; 12(4): 53-67
Published online Jul 20, 2022. doi: 10.5493/wjem.v12.i4.53
Published online Jul 20, 2022. doi: 10.5493/wjem.v12.i4.53
NCT number | Drug | Mechanism of action | Status | Sponsor |
NCT04395456 | AMY-101 | C3 inhibitor | Not yet recruiting | Amyndas Pharmaceuticals S.A. |
NCT04402060 | APL-9 | C3 inhibitor | Completed | Apellis Pharmaceuticals, Inc. |
NCT04346797 | Eculizumab | C5 inhibitor | Recruiting | Assistance Publique- Hôpitaux de Paris |
NCT04355494 | Eculizumab | C5 inhibitor | Expanded access no longer available | Alexion Pharmaceuticals |
NCT04288713 | Eculizumab | C5 inhibitor | Expanded access available | Hudson Medical |
NCT04351503 | Eculizumab | C5 inhibitor | Recruiting | University Hospital, Basel, Switzerland |
NCT04369469 | Ravulizumab | C5 inhibitor | Terminated (Met futility bar at interim analysis) | Alexion Pharmaceuticals |
NCT04382755 | Zilucoplan (RA101495) | C5 inhibitor | Completed | University Hospital, Ghent |
NCT04371367 | Avdoralimab | Anti-C5aR | Completed | Assistance Publique Hopitaux De; Marseille &Innate Pharma |
NCT04414631 | Conestat alfa | C1 esterase inhibitors | Terminated | University Hospital, Basel, Switzerland & Pharming Technologies B.V. |
NCT04530136 | Ruconest | C1 esterase inhibitors | Recruiting | Pharming Technologies B.V. |
NCT04333420 | Vilobelimab (IFX-1) | C5a | Recruiting | InflaRx GmbH |
NCT04570397 | Ravulizumab | C5 inhibitor | Recruiting | Brigham and Women's Hospital |
NCT04390464 | Ravulizumab | C5 inhibitor | Recruiting | Cambridge University Hospitals NHS; Foundation Trust; Frances Hall |
- Citation: Gianni P, Goldin M, Ngu S, Zafeiropoulos S, Geropoulos G, Giannis D. Complement-mediated microvascular injury and thrombosis in the pathogenesis of severe COVID-19: A review. World J Exp Med 2022; 12(4): 53-67
- URL: https://www.wjgnet.com/2220-315x/full/v12/i4/53.htm
- DOI: https://dx.doi.org/10.5493/wjem.v12.i4.53